Acute COVID-19 does not affect corneal sensitivity, study finds

Article

Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

Acute COVID-19 does not affect corneal sensitivity, study finds

Brazilian researchers reported recently that the corneal esthesiometry findings did not differ significantly between patients who had positive and negative polymerase chain reaction (PCR) results for COVID-19, indicating that the acute infection did not impact the ability to obtain reliable test results.1

A team of investigators, led by Dr Lucas Baldissera Tochetto from the Department of Ophthalmology and Visual Science at Federal University of Sao Paulo in Sao Paulo, Brazil, reported their results in the British Journal of Ophthalmology.

A number of ocular manifestations of COVID-19 have previously been reported, and Dr Tochetto pointed out that SARS-CoV-2 RNA was found in the tear film or conjunctival swabs in patients tested using PCR.2 Based on that, the investigators theorized that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

A total of 202 individuals who were suspected of having COVID-19 based on symptomatology participated in this cross-sectional study. All subjects underwent testing for SARS-CoV-2 by nasopharyngeal reverse-transcription qualitative PCR.

All patients also underwent corneal esthesiometry measurements using the Cochet-Bonnet esthesiometer (Luneau Ophthalmologie) during their first visit and the measurements were analyzed based on the findings, presence of anosmia and dysgeusia, and ocular signs and symptoms, Dr Tochetto said.

PCR testing and corneal sensitivity

PCR identified COVID-19 infections in 101 subjects (50%). The mean corneal esthesiometry findings based on the PCR results did not differ significantly when the baseline and first follow-up visit were compared, demonstrating that the virus did not affect the corneal esthesiometry in individuals with acute-phase COVID-19. The mean time from symptom onset to disease diagnosis and corneal esthesiometry was 4.2 days, he noted.

Fifty of the patients who tested positive for COVID-19 also were examined a second time. The mean time between the first to second visits was 32.5 days. The mean respective corneal esthesiometry measurements in the right eye at the 2 evaluations were 5.52 and 5.60 (p=0.616) and for the left eye 5.40 and 5.58 (p=0.173).

The authors concluded that their results indicated that the SARS-CoV-2 infection did not interfere with corneal esthesiometry, at least, in the mild and early stages of this disease.

References
1. Baldissera Tochetto L, de Freitas Santoro D, Hirai F, et al. Impact of COVID-19 on corneal esthesiometry. Br J Ophthalmol 2022; http://dx.doi.org/10.1136/bjophthalmol-2021-320003
2. Sarma P, Kaur H, Kaur H, et al. Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID-19: a systematic review and meta-analysis. SSRN Electron J 2020; doi:10.2139/ssrn.3566161
Recent Videos
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.